Analysis of U.S. Patent 8,318,706: Plerixafor Octa-Acetate and its Patent Landscape
U.S. Patent 8,318,706, titled "Plerixafor octa-acetate and processes for preparing same," was granted on November 28, 2012, to Genzyme Corporation, now a subsidiary of Sanofi. This patent covers a specific chemical form of plerixafor, known as plerixafor octa-acetate, and methods for its preparation. Plerixafor, marketed as Mozobil, is a hematopoietic stem cell mobilizer used in conjunction with granulocyte-colony stimulating factor (G-CSF) to increase peripheral blood stem cell counts in patients with non-Hodgkin's lymphoma and multiple myeloma prior to autologous stem cell transplantation [1]. The patent's scope is critical for understanding the exclusivity period and potential market dynamics surrounding this therapeutic agent.
What are the Core Claims of U.S. Patent 8,318,706?
The central claims of U.S. Patent 8,318,706 define a specific chemical entity and its preparation. The patent does not claim the plerixafor molecule itself, as the parent compound was previously disclosed. Instead, it focuses on a particular salt form and its manufacturing processes.
- Claim 1: This independent claim defines "Plerixafor octa-acetate." This is the primary subject matter of the patent, specifying a precise chemical composition.
- Claim 2: This claim is dependent on claim 1 and further defines plerixafor octa-acetate, likely by specifying purity levels, polymorphic forms, or other characteristics that distinguish it from less refined versions.
- Claim 3: This claim describes a "process for preparing plerixafor octa-acetate." This focuses on the manufacturing methodology, providing protection for the specific steps and conditions used to synthesize the claimed compound.
- Claims 4-10: These claims are dependent on claim 3, further detailing specific aspects of the preparation process. This can include particular reagents used, reaction conditions (temperature, pressure, solvent), purification techniques, or isolation methods. For example, a claim might specify a particular solvent system or a particular pH range for a reaction step.
The patent's claims are designed to provide a strong layer of protection by covering both the specific chemical entity and the means by which it is produced, thereby making it more challenging for competitors to design around.
What is the Chemical Scope of Plerixafor Octa-Acetate?
Plerixafor octa-acetate is a salt form of plerixafor, which is a bicyclam molecule (1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]). Plerixafor itself is known for its ability to antagonize the CXCR4 chemokine receptor. The octa-acetate form refers to the counter-ions associated with the basic nitrogen atoms in the plerixafor molecule. The precise stoichiometry and structure of the octa-acetate salt are central to the patent's definition of the compound.
The chemical structure of plerixafor is:
C₂₄H₄₀N₆
The octa-acetate form implies that eight acetate ions (CH₃COO⁻) are associated with the plerixafor molecule. The formation of specific salt forms can confer desirable properties such as improved stability, solubility, or handling characteristics, which are often the basis for patent protection. The patent likely specifies the formation and characterization of this particular salt, differentiating it from the free base or other potential salt forms of plerixafor.
What is the Regulatory Status and Market Impact of Plerixafor?
Plerixafor, under the brand name Mozobil, received U.S. Food and Drug Administration (FDA) approval on December 15, 2008 [2]. It is indicated for use in patients with non-Hodgkin's lymphoma and multiple myeloma undergoing autologous stem cell transplantation. Its role is to enhance the mobilization of peripheral blood stem cells to the bloodstream, facilitating their collection for transplantation.
The market for stem cell mobilization agents is significant, particularly within the oncology sector. The exclusivity provided by U.S. Patent 8,318,706 is crucial for Genzyme/Sanofi to recoup its R&D investments and maintain market share. The existence of this patent has implications for the development and market entry of generic versions of plerixafor.
What is the Exclusivity Period for U.S. Patent 8,318,706?
U.S. Patent 8,318,706 was granted on November 28, 2012. Standard patent terms in the United States are 20 years from the filing date. Assuming a typical 3-year prosecution period, the original filing date would be around 2009.
- Filing Date: Approximately 2009 (exact date needs verification from USPTO records).
- Grant Date: November 28, 2012.
- Expected Expiration Date: Approximately 20 years from the filing date, placing the expiration around 2029.
It is important to note that patent terms can be extended under certain circumstances, such as through the Hatch-Waxman Act for regulatory review delays (Patent Term Adjustment) or via patent term extensions for specific pharmaceutical patents (Patent Term Extension). For drugs like plerixafor, these extensions can be significant. For instance, if plerixafor received a Patent Term Extension (PTE), the patent term could be extended by a portion of the time lost due to FDA review.
The effective market exclusivity for plerixafor is determined by the expiration of all relevant patents covering the drug and its uses, not solely U.S. Patent 8,318,706. However, this specific patent, by covering a particular salt form and its preparation, contributes to the overall IP barrier.
Who are the Key Players in the Plerixafor Patent Landscape?
The primary patent holder for plerixafor octa-acetate is Sanofi (through its subsidiary Genzyme Corporation). Understanding the patent landscape involves identifying potential challengers, generic manufacturers, and other entities that may hold patents related to plerixafor or its therapeutic uses.
- Sanofi/Genzyme: The owner of U.S. Patent 8,318,706 and the originator of Mozobil.
- Generic Manufacturers: Companies that may seek to produce generic versions of plerixafor once patents expire or are successfully challenged. These include entities such as Teva Pharmaceuticals, Mylan N.V., and others that specialize in generic drug development and manufacturing.
- Research Institutions and Other Pharmaceutical Companies: While less common for a specific salt form, other entities might hold patents related to alternative salt forms, novel formulations, or new therapeutic indications for plerixafor.
A thorough freedom-to-operate analysis would be required to identify any potential infringement of other patents by generic manufacturers. This would involve searching for patents covering:
- The plerixafor molecule itself (if any are still in force or were never fully resolved).
- Other salt forms of plerixafor.
- Specific pharmaceutical compositions or formulations of plerixafor.
- Methods of treatment using plerixafor.
What is the Competitive Landscape for Stem Cell Mobilization Agents?
The market for stem cell mobilization is primarily dominated by G-CSF (e.g., Neupogen, Neulasta) and plerixafor (Mozobil). The combination therapy of G-CSF and plerixafor is the standard of care for certain patient populations.
- G-CSF Agents: Numerous patents exist for G-CSF molecules and their formulations. The market for G-CSF has seen significant generic competition.
- Plerixafor (Mozobil): Currently benefits from patent protection, including U.S. Patent 8,318,706. Its exclusivity period directly impacts the market entry timeline for potential generic plerixafor products.
The introduction of generic plerixafor is anticipated to increase market competition and potentially lower prices, expanding access for eligible patients. The timing of this entry will be dictated by patent expiration dates, successful patent challenges, or regulatory approvals for generic versions.
What are the Potential Patent Challenges and Litigation Risks?
Patents, especially those covering valuable pharmaceutical products, are frequently subject to legal challenges. For U.S. Patent 8,318,706, potential challenges could arise from generic manufacturers seeking to enter the market.
- Invalidity Challenges: Generic companies may attempt to invalidate the patent by arguing that the claimed invention was not novel, was obvious, or lacked sufficient written description at the time of filing. This could involve prior art searches to uncover previously disclosed information about plerixafor octa-acetate or its preparation.
- Infringement Litigation: Sanofi would likely defend its patent by asserting that generic products infringe its claims. Litigation would involve detailed analysis of the generic product's composition and manufacturing process against the patent claims.
- Inter Partes Review (IPR): This administrative trial proceeding at the U.S. Patent and Trademark Office (USPTO) provides an avenue for third parties to challenge the validity of granted patents. IPRs can be a faster and less expensive route than district court litigation for challenging patent claims.
The strength of the patent's claims, the quality of the prior art, and the prosecution history of the patent will all factor into the likelihood and success of any legal challenges. The specific details of the "process for preparing plerixafor octa-acetate" claims will be critical in any infringement or validity dispute.
What is the Future Outlook for Plerixafor and its Patent Landscape?
The future outlook for plerixafor is tied to the ongoing patent exclusivity and the eventual market entry of generics.
- Continued Market Exclusivity: Until the expiration of U.S. Patent 8,318,706 and any other relevant patents, Sanofi will maintain market exclusivity for plerixafor.
- Generic Entry: Once patent protection lapses, generic manufacturers will likely seek FDA approval for their plerixafor products. This is expected to lead to increased competition and a reduction in drug prices.
- Potential for New Indications: While not directly covered by this patent, research into new therapeutic uses for plerixafor could extend its commercial lifecycle and lead to new patent filings for those specific applications.
The commercial success of plerixafor octa-acetate, as protected by this patent, is a testament to the value of securing intellectual property for specific chemical forms and manufacturing processes. The patent landscape for plerixafor is dynamic and will continue to evolve as existing patents expire and new IP is potentially generated.
Key Takeaways
- U.S. Patent 8,318,706 protects plerixafor octa-acetate and its preparation processes, not the plerixafor molecule itself.
- The patent's claims are critical for Sanofi's market exclusivity of Mozobil, a stem cell mobilizer.
- The patent is expected to expire around 2029, subject to potential extensions.
- Generic manufacturers may challenge the patent's validity or seek to design around its claims upon expiration.
- The patent landscape for plerixafor includes originator patents and potential future challenges from generic competitors.
Frequently Asked Questions
-
Does U.S. Patent 8,318,706 cover the use of plerixafor to treat non-Hodgkin's lymphoma?
No, this patent specifically covers the chemical compound plerixafor octa-acetate and its preparation methods. Separate patents or regulatory exclusivities may cover methods of treatment.
-
When did the FDA first approve plerixafor (Mozobil)?
Plerixafor (Mozobil) received U.S. FDA approval on December 15, 2008.
-
Can generic companies produce plerixafor before U.S. Patent 8,318,706 expires?
Generic companies can only produce and market generic versions of plerixafor if all relevant patents, including U.S. Patent 8,318,706, have expired or have been successfully invalidated or found not to be infringed.
-
What is the significance of the "octa-acetate" designation in the patent?
The "octa-acetate" designation specifies a particular salt form of plerixafor, characterized by the association of eight acetate ions with the plerixafor molecule. This specific salt form, along with its preparation methods, is the subject of the patent claims.
-
Are there other patents protecting plerixafor or its uses?
It is highly probable that other patents exist covering different aspects of plerixafor, such as the base molecule, alternative salt forms, specific formulations, or methods of treatment. A comprehensive freedom-to-operate analysis is necessary to assess the full patent landscape.
Citations
[1] Mozobil® (plerixafor) injection. (2008). Prescribing Information. Genzyme Corporation.
[2] U.S. Food & Drug Administration. (2008, December 15). FDA approves Mozobil for stem cell mobilization. [Press release].
